--:--:--

Ajanta Pharma Limited

Web: ajantapharma.com NSE: AJANTPHARM BSE: 532331 SECTOR: Healthcare - Pharmaceuticals & Biotechnology | Add Note | View Notes

3260 39(-1%)

Volume

38k as on 16, Oct

Open

2,662

High

3,030

Low

2,892

Close

3,299

VWAP

3,339

52 Week High

3,796

52 Week Low

2,382

Viand Research Rating
Quality Score

54/100

Growth Score

42/100

Valuation Score

50/100

Momentum Score

25/100

Analyst Recommendations

BUY/SELL

Hold | Buy | Strong Buy
Analyst Price Target
-
Market Cap (cr)

40,735

No. of Shares

12.5

P/E

42.84

P/B

10.36

Face Value

2

Div. Yield

-

Book Value (TTM)

-

CASH

-

DEBT

-

EPS (TTM)

-

ROE

24.19

ROCE

-

Profit Growth

-

Listing Date

29-May-00

Rank/Sector Rank

#224/#22

Promoter Holding

66.25%

FII Holding

8.26%

DII Holding

18.36%

Price Chart
Price Performance
1 Week2%
1 Month5%
3 Months4%
6 Months18%
1 Year37%
YTD13%
Moving Average
5 Day SMA3,343
10 Day SMA3,419
20 Day SMA3,488
30 Day SMA3,498
50 Day SMA3,531
61 Day SMA3,513
80 Day SMA3,480
200 Day SMA3,140
PIVOT LEVEL
StandardCamarillaFibonacciWoodie's
Resistance 33,4683,3803,4283,484
Resistance 23,4283,3733,3993,436
Resistance 13,3943,3663,3823,410
Pivot Point3,3543,3593,3543,362
Support 13,3203,3533,3253,336
Support 23,2803,3463,3083,288
Support 33,2463,3393,2803,262
Competitors/Peers
#SymbolMCAPLTP1W1M6M1YP/EInd PEDebt/EqNP Qtr Rs.Cr.
1SUNPHARMA4,18,69817450%5%4%4%3755.50.0711509
2DIVISLAB2,43,96691902%0%45%38%6955.502568
3TORNTPHARM1,73,20845542%5%10%28%7255.51.792138
4ZYDUSLIFE1,11,45111170%1%20%12%2055.50.313560
5APOLLOHOSP1,09,27676002%9%4%1%5855.50.92003
6LAURUSLABS1,08,73820121%8%83%124%055.50.48890
7CIPLA1,06,15413142%2%8%19%2255.50.023862
8DRREDDY1,03,87312443%8%1%4%2055.50.24158
9MANKIND94,40122864%1%8%7%4955.50.391938
10AUROPHARMA90,84115792%1%20%52%055.50.192415
Load More
Shareholding Pattern (%)
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021
Promoters(0.01) 66.25%(0.01) 66.25%(0.01) 66.25%(0.01) 66.26%(0.01) 66.26%(0.01) 66.26%(0.01) 66.26%(0.01) 66.27%(0.01) 66.22%(0.01) 66.22%(0.01) 66.22%(0.11) 66.22%(0.01) 66.11%(-4.41) 66.11%(0.01) 70.48%(0.01) 70.48%(0.11) 70.48%(0.01) 70.34%(0.01) 70.34%
FIIs(0.31) 8.26%(-0.61) 7.97%(-0.31) 8.53%(0.01) 8.86%(-0.41) 8.86%(0.21) 9.26%(0.81) 9.11%(-0.21) 8.36%(-0.61) 8.54%(-0.91) 9.11%(-0.21) 9.99%(0.21) 10.19%(-0.11) 10.00%(1.81) 10.07%(-0.11) 8.23%(-0.31) 8.30%(-0.31) 8.64%(0.21) 8.95%(0.01) 8.72%
DIIs(-0.21) 18.36%(0.71) 18.58%(0.41) 17.90%(0.01) 17.50%(0.51) 17.48%(-0.11) 17.02%(-0.31) 17.09%(-0.11) 17.41%(0.81) 17.48%(1.11) 16.67%(0.21) 15.60%(-0.21) 15.36%(0.21) 15.52%(2.71) 15.37%(0.21) 12.68%(0.21) 12.46%(0.11) 12.29%(0.11) 12.14%(0.01) 12.07%
Government0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.00%0.00%0.00%0.46%0.45%0.45%0.45%0.45%0.45%0.45%0.43%
Public7.14%7.20%7.32%7.38%7.38%7.45%7.51%7.94%7.76%8.00%8.21%7.78%7.91%8.00%8.15%8.31%8.14%8.12%8.43%
No. of Shareholders67,95565,40967,78568,88270,82766,89664,31570,31655,48854,35156,27754,87483,54959,79862,04864,44560,75957,89752,263
Quarterly Results
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021
Sales142213751354130311701146118711451054110510281021882972938951870838885748
Sales Growth % (YoY)21.5%20%14.1%13.8%11%3.7%15.4%12.1%19.5%13.7%9.6%7.4%1.3%16%6%27.1%15%11.9%23.6%11.9%
Sales Growth % (QoQ)3.4%1.6%3.9%11.4%2.1%-3.5%3.7%8.6%-4.6%7.5%0.7%15.8%-9.3%3.6%-1.4%9.3%3.8%-5.3%18.3%-
Expenses10889931026951873825875815776791738750732802742729664598622528
Operating Profit333382328351297321311330278314291271149170196222207240263220
OPM %2328242725282629262828271717212324293029
Other Income6125592618301926361421323735403329243033
Interest25356861222113117102
Depreciation4544434140363434343434333333333231323231
Profit before tax347359341331269307290322278291276269152168203222198231260220
Tax %2324242316242524272829232020232124172521
Net Profit 267274260255225233216246203210195208122135157175151192196174
Net Profit Growth % (QoQ)-2.6%5.4%2%13.3%-3.4%7.9%-12.2%21.2%-3.3%7.7%-6.2%70.5%-9.6%-14%-10.3%15.9%-21.4%-2%12.6%-
Net Profit Growth % (YoY)18.7%17.6%20.4%3.7%10.8%11%10.8%18.3%66.4%55.6%24.2%18.9%-19.2%-29.7%-19.9%0.6%----
TTM Net Profit105610149739299208988758548167356606225896186757147135623700
EPS in Rs21.3521.9120.8320.4418.0318.6417.3319.6815.8216.3915.2416.249.5410.512.2213.6311.814.7815.113.39
Profit and Loss
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014Mar 2013
Sales5453464842093743334128902588205521261983174914741208931
Sales Growth %17.3%10.4%12.4%12%15.6%11.7%25.9%-3.3%7.2%13.4%18.7%22%29.8%37.4%
Expenses40583379303729342408188919041489146712921155968840706
Operating Profit1395126911728089331001683567658691594505369224
OPM %2627282228352628313534343124
Other Income1728585741122488212420148146
Interest1621761081210156919
Depreciation1731441351311251169672606144524434
Profit before tax137811891114745909900664514623648559456330177
Tax %2323272122273025252226322937
Net Profit 1056920816588713654468387469507416310234112
Net Profit Growth %14.8%12.7%38.8%-17.5%9%39.7%20.9%-17.5%-7.5%21.9%34.2%32.5%108.9%-
EPS in Rs84.5273.6863.745.8955.6350.3835.7329.5635.538.431.4923.4717.758.49
Dividend Payout %03879151113242002317171513
Cash Flows
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014Mar 2013
Cash from Operating Activity01157785792562576457375281609326279212234
Cash from Investing Activity0-37765-560-74-282-224-223-256-383-209-158-188-104
Cash from Financing Activity0-733-1051-108-460-318-129-1470-202-117-105-20-104
Net Cash Flow047-20112428-2410442524016426
Balance Sheet
Mar 2026Sep 2025Mar 2025Sep 2024Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014Mar 2013
Equity Capital25252525252517171818181818181812
Reserves4502429037653652354233633247297825812228202415501173823576382
Borrowings2602464733353625317536218172130125
Other Liabilities13681112106710819271159711702619383383254207233226200
Total Liabilities61555672490447904530458240003729329326642426182314791146949718
Fixed Assets18671873176214511479149615121541147211781053589451288279273
CWIP258146176349256209153108132262613392401709412
Investments58887446470234953514717679781901828660638
Other Assets34412779250222892446234121881904161011471122713703629513425
Total Assets61555672490447904530458240003729329326642426182314791146949718
Delivery

Delivery Data: AJANTPHARM

#Date
3250
17%
3796
Value (Cr)Q/T
7		Del
52		Del
23
121-Oct3260
17
37012
219-Oct3299
12
3506
316-Oct3329
13
3547
415-Oct3359
35
65519
514-Oct3299
25
45414
613-Oct3328
18
87413
712-Oct3399
31
56420
89-Oct3410
42
46025
98-Oct3436
29
44814
107-Oct3570
33
45318
116-Oct3573
39
45321
125-Oct3486
37
55320
131-Oct3581
27
54612
1430-Sep3621
126
62937
1529-Sep3558
30
54814
1628-Sep3525
34
55118
1725-Sep3548
16
56711
1824-Sep3540
13
4456
1923-Sep3568
11
5505
2022-Sep3519
37
85420
2121-Sep3542
48
115024
2218-Sep3564
72
56043
2317-Sep3500
34
66422
2416-Sep3509
41
67531
2515-Sep3510
27
67019
2611-Sep3533
16
3559
2710-Sep3520
7
4322
289-Sep3534
15
4426
298-Sep3579
40
75622
307-Sep3514
26
55915
314-Sep3465
23
66314
323-Sep3521
15
3406
332-Sep3482
34
65920
341-Sep3505
31
54815
3531-Aug3602
22
65212
3628-Aug3557
14
3527
3727-Aug3544
18
46211
3826-Aug3552
13
6567
3925-Aug3555
41
65924
4024-Aug3580
24
55313
4121-Aug3640
19
3489
4220-Aug3659
25
4369
4319-Aug3698
31
5299
4418-Aug3706
54
75027
4517-Aug3718
41
45221
4614-Aug3673
35
55218
4713-Aug3615
50
64020
Daily Market Cap
DateTotal Market CapChangeChg %
21-Oct40,735c451c1.10
19-Oct41,187c302c0.73
17-Oct41,489c00
16-Oct41,489c495c1.18
15-Oct41,984c120c0.28
14-Oct42,104c605c1.46
13-Oct41,499c987c2.32
12-Oct42,486c126c0.30
09-Oct42,612c311c0.72
08-Oct42,923c1,130c2.56
05-Oct44,053c71c0.16
01-Oct43,982c187c0.43
29-Sep43,794c141c0.32
28-Sep43,936c167c0.38
25-Sep44,103c556c1.25
24-Sep44,659c542c1.23
22-Sep44,117c334c0.76
17-Sep43,783c79c0.18
10-Sep43,704c216c0.49
07-Sep43,921c00
Stock Checklist
Price is above from 52 week high low average: 62%
Stock is trading above all short term SMAs: NO
Stock is trading above all long term SMAs: YES
Stock is Consistently Improving Long Term: NO
FII purchased in last quarter: YES
Promoters are buying the stock: NO
Mutual Fund Holdings

Held by 331 fund scheme(s) across 36 fund house(s) as of Oct26 · Total value ₹15,993 Cr · 243 increasing / 36 decreasing · View in MF Pro →

Fund HouseSchemesWeight %ChangeValue (Cr)
Kotak Mahindra Mutual Fund181.31%+0.07%2916.3
UTI Mutual Fund361.79%+0.11%2589.2
Nippon India Mutual Fund100.83%+0.05%2435.9
Aditya Birla Sun Life Mutual Fund300.91%+0.09%2006.9
Canara Robeco Mutual Fund101.26%+0.08%1267.6
HDFC Mutual Fund160.84%+0.06%912.3
Edelweiss Mutual Fund201.20%+0.07%798
SBI Mutual Fund100.99%+0.01%643.4
WhiteOak Capital Mutual Fund180.66%+0.30%458.4
Abakkus Mutual Fund22.07%+0.15%324.2
PGIM India Mutual Fund121.24%+0.11%312.8
Union Mutual Fund221.52%+0.12%294.1
NJ Mutual Fund41.97%+0.11%227.6
Baroda BNP Paribas Mutual Fund121.26%+0.03%219.3
Mahindra Manulife Mutual Fund41.34%+0.05%178
Tata Mutual Fund81.23%+0.08%79.8
Franklin Templeton Mutual Fund21.76%+0.08%76
Bandhan Mutual Fund160.22%-0.20%74.8
Motilal Oswal Mutual Fund80.28%+0.07%40.6
Bank of India Mutual Fund20.78%-0.05%33.3
Samco Mutual Fund24.14%+0.85%19.8
Sundaram Mutual Fund21.20%+1.20%19
ICICI Prudential Mutual Fund80.47%+0.09%17
DSP Mutual Fund61.62%-15.1
Shriram Mutual Fund120.87%-0.48%9.4
Navi Mutual Fund80.53%+0.05%7.6
LIC Mutual Fund80.50%+1.53%4.5
Zerodha Mutual Fund40.20%+0.02%3.8
ITI Mutual Fund21.32%-3.1
PGIM India Asset Management Private Limite11.22%+0.06%2.1
Jio BlackRock Mutual Fund20.31%+0.04%1.3
Angel One Mutual Fund40.45%+0.05%0.9
Groww Mutual Fund40.09%+0.02%0.7
Axis Mutual Fund20.09%+0.01%0.5
Mirae Asset Mutual Fund40.13%+0.02%0.2
The Wealth Company Mutual Fund20.00%-0.96%0
Strategy Builder
Bulk Deals
Events
News
Exchange Filings
Annual Reports
Ratings & Research Reports
Concalls
Announcements
For research & education only — not investment advice. Not a SEBI-registered Investment Adviser or Research Analyst. Data may be delayed or inaccurate. Investments in securities markets are subject to market risks.
0